Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine effects on mucosal immune biomarkers in diarrhea-predominant irritable bowel syndrome
IRCT2012072910230N2Phase 3Completed
- Sponsor
- Digestive and Liver Disease Research Center
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Salcrozine in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Digestive and Liver Disease Research Center. Primary endpoint: Mucosal immune biomarkers. Started Mar 2011; status: completed.
02
Drugs
Salcrozine
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on IRCT2012072910230N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2012072910230N2.